SLC2A1 and esophageal cancer: Sawayama H. et al. [78] studied the influence of GLUT-1 inhibition on cisplatin response in esophageal cancer and found that the inhibition of GLUT-1 using miRNAs or specific inhibitors improved the sensitivity to low dose cisplatin treatment [44,78].